Riverbridge Partners LLC Reduces Stock Position in Charles River Laboratories International, Inc. $CRL

Riverbridge Partners LLC lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 20.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 99,328 shares of the medical research company’s stock after selling 25,976 shares during the quarter. Riverbridge Partners LLC owned approximately 0.20% of Charles River Laboratories International worth $19,814,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hantz Financial Services Inc. grew its holdings in shares of Charles River Laboratories International by 11.2% in the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after purchasing an additional 80 shares during the last quarter. Advisory Services Network LLC lifted its holdings in Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after buying an additional 83 shares in the last quarter. Rothschild Investment LLC lifted its holdings in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Charles River Laboratories International by 4.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock valued at $332,000 after buying an additional 85 shares during the period. Finally, Resona Asset Management Co. Ltd. boosted its position in Charles River Laboratories International by 17.5% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock valued at $86,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. TD Cowen reduced their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Finally, UBS Group upped their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $206.15.

Charles River Laboratories International Price Performance

Shares of CRL opened at $165.23 on Friday. The company has a 50 day moving average price of $180.82 and a 200-day moving average price of $180.55. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The stock has a market capitalization of $8.13 billion, a PE ratio of -55.82, a PEG ratio of 2.84 and a beta of 1.64. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. Charles River Laboratories International’s revenue was down .8% compared to the same quarter last year. During the same period last year, the company posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.